Counterfeit hope or bridging the gap? Ethical challenges in patient-sourced topical ruxolitinib for vitiligo
Clinical and Experimental Dermatology · 2026-09-10
DOI: 10.1093/ced/llag304 ↗Abstract
This ethical dilemma proposes a clinical scenario involving a patient with vitiligo who has independently accessed a novel topical therapy from an unregulated overseas source, reporting noticeable improvement. This article explores the complex ethical tensions that arise when patient autonomy, treatment accessibility and medication safety intersect in real-world dermatology practice.
EUVIMED